Alex H
11年前
I am long TRGT. Why? Just announced failed phase 2 trial and stock got wallopped. Not sure what prospects the stock has going forward but its trading at cash value. Market cap of $157 million versus $143 million in cash as of 12/31/2013. More importantly in the last quarter Wellington Management, Vanguard, Deerfield Management, Dimensional fund, DE Shaw, State Street, Fidelity, and Goldman Sachs all initiated or increased existing positions. Something is most certainly up. Value investors should be looking.
surf1944
12年前
7:50AM Targacept reports EPS in-line (TRGT) 5.21 : Reports Q2 (Jun) GAAP loss of $0.37 per share, in-line with the GAAP Capital IQ Consensus Estimate consensus of ($0.37). No revs were reported
"With recruitment completed this quarter in two ongoing Phase 2b clinical trials and tracking ahead of our initial planning assumptions in a third, we anticipate having three clinical readouts between December 2013 and the middle of 2014. Specifically, we expect to report top-line results from our study of TC-5619 as a treatment for negative symptoms and cognitive dysfunction in schizophrenia in either December 2013 or January 2014, top-line results from our study of TC-5214 as a treatment for overactive bladder in the first half of 2014 and top-line results from our study of TC-1734 in mild to moderate Alzheimer's disease in mid-2014,"
surf1944
12年前
7:06AM Targacept and AstraZeneca (AZN) amend collaboration; Targacept now has the right to pursue development and commercialization of any alpha7 NNR modulator (TRGT) 4.28 : The cos announced that its collaboration with AstraZeneca has been restructured. Under the new terms:
Targacept now has the right to pursue development and commercialization of any alpha7 NNR modulator in any therapeutic area, including cognitive disorders and schizophrenia, without obligation to AstraZeneca. Previously, AstraZeneca held an option to license any such compound that was developed by Targacept for a cognitive disorder or schizophrenia. Targacept has several alpha7 NNR modulators in its portfolio.
AstraZeneca now has the right to develop and commercialize the alpha4beta2 NNR modulators that it has licensed from Targacept under the collaboration, including AZD1446, in any therapeutic area. Previously, AstraZeneca's rights with regard to these compounds were limited to cognitive disorders and schizophrenia.
AstraZeneca will return to Targacept all rights to the alpha4beta2 modulator TC-1734 (also known as AZD3480), which is currently in a Phase 2b clinical trial in mild to moderate Alzheimer's disease.
mlkrborn
12年前
Didnt meet the primary objective
UPDATE 1-Targacept attention deficit drug fails study; jobs cut
Reuters - UK FocusReuters - UK Focus – 2 hours 1 minute ago
Email
Print
Companies:
ASTRAZENECA
Targacept Inc.
RELATED QUOTES
Symbol Price Change
AZN.L 2,888.50 -4.50
TRGT 4.31 -0.54
* Targacept ADHD drug fails to meet goal of mid-stage trial
* Company to cut undisclosed number of jobs
* Targacept (NasdaqGM: TRGT - news) to limit development of nicotinic pipeline
* Shares fall as much as 12.4 percent (Adds background about previous drug failures, adds bullet points)
Sept 17 (Reuters) - An experimental treatment for attention deficit hyperactivity disorder from Targacept Inc did not meet the main goal of a mid-stage trial, prompting the company to drop development of the drug and cut jobs.
Targacept shares fell as much as 12.4 percent on Monday after the results showed that patients in the placebo group had improved more than those taking the experimental drug, TC-5619.
The company did not specify how many people it would lay off, but said it would limit investment in the development of certain products in its pipeline until it appoints a new chief executive officer.
In June, CEO Donald deBethizy stepped down. His role is being assumed by Chairman Mark Skaletsky pending the appointment of a new CEO.
DeBethizy's departure followed disappointing results from trials of Targacept's treatments for diabetes and asthma, which prompted the company to cut its workforce by 46 percent, or 65 jobs.
In March, Targacept and partner AstraZeneca (LSE: AZN.L - news) said they would abandon work on the their experimental antidepressant after it failed to meet key goals in two late-stage clinical studies.
Targacept shares were down 10.7 percent at $4.33 in Monday morning trading after falling to $4.25 earlier in the session. (Reporting by Vidya P L Nathan in Bangalore and Toni Clarke in Boston; Editing by Joyjeet Das and Lisa Von Ahn)'
surf1944
13年前
8:57AM Targacept announces revised top-line results from exploratory Phase 2 study of TC-6987 in asthma: study no longer achieves protocol-defined success criteria on primary endpoint of Forced Expiratory Volume (TRGT) 4.85 : Co announced revised top-line results from its exploratory Phase 2 clinical study of TC-6987 in asthma. Following identification of an error in the application of the agreed statistical analysis plan, a reanalysis of the data was undertaken. As compared to the initially reported values, the reanalysis revealed a 2 ml decrease in the change in Forced Expiratory Volume (FEV1) from baseline to pre-dosing on day 28, which resulted in TC-6987 no longer achieving the study's protocol-defined success criteria on that co-primary endpoint. However, TC-6987 continued in the reanalysis to meet protocol-defined success criteria on the study's other co-primary endpoint, change in FEV1 from baseline to two hours post-dosing on day 28. Reanalysis of the post-dose measure revealed an incrementally stronger signal of a drug effect than the initial analysis.
surf1944
13年前
8:06AM Targacept announces 'Top-line' results from two exploratory Phase 2 studies of TC-6987; co will not pursue further development of TC-6987 as a treatment for diabetes (TRGT) 5.41 : Co announced top-line results from two separate exploratory Phase 2 studies of its product candidate TC-6987 conducted in the United States, one in asthma and one in type 2 diabetes. In the asthma study, oral TC-6987 met protocol-defined success criteria on both co-primary outcome measures, change from baseline in forced expiratory volume for adjunct TC-6987 compared to adjunct placebo measured at two time points on day 28. TC-6987 was generally well tolerated in both studies. There were no clinically meaningful changes in cardiovascular parameters in either study, an important finding that differentiates TC-6987 from many other alpha7 modulators. Co-Primary Endpoints in Asthma Study Achieved. In the type 2 diabetes study, the primary outcome measure, change in fasting plasma glucose, was not met, and Targacept will not pursue further development of TC-6987 as a treatment for diabetes. TC-6987 is a modulator of the alpha7 neuronal nicotinic receptor discovered by Targacept scientists using Pentad, the company's proprietary drug discovery platform.
dav1234
13年前
Well TRGT actually trading below cash ,really beat up on the phase 3 failure,but they have a few other phase 2s due by summer ,should rebound a bit if some analysts sound off on cash and potential,not going back to 30 but 7 or so would be nice,would hopefully like to ride a few free and then lets chips fall where they may with the rest of their pipeline
mlkrborn
13年前
Astra quits but TRGT prepared; Purse other avenues with 225 m. cash!
AstraZeneca, Targacept end work on depression drug
AstraZeneca, Targacept ending development of depression drug after disappointing trial
Associated PressAssociated Press – 6 minutes ago
Targacept, Inc.
RELATED QUOTES
Symbol Price Change
TRGT 5.695 -1.71
LONDON (AP) -- Drug makers AstraZeneca and North Carolina-based Targacept have abandoned plans to seek regulatory approval for a drug intended to treat major depressive disorder, the companies said Tuesday.
AstraZeneca said that the drug TC-5214 did not perform as hoped in an eight-week trial compared to a placebo. The announcement caused little surprise, following disappointing trials last year, but was a blow nevertheless for Targacept, the smaller of the two companies. Its shares dropped 14 percent in premarket trading in New York.
AstraZeneca, which said it will take an impairment charge of $50 million on the drug's failure, saw its shares fall only 1 percent to 2,830 pence in London.
TC-5214, which was not expected to be a blockbuster, was being tested as a supplementary treatment for major depressive disorder in patients who did not respond to the most common type of antidepressants, selective serotonin reuptake inhibitors. It was intended to work on neuronal nicotinic receptors, which regulate the nervous system.
Had the drug succeeded, sales would have been less than $100 million a year in 2016, according to analyst projections.
Dr. Mike Mitchell, health care expert at Seymour Pierce & Co., said the news underlined the difficulties of making progress in neuroscience.
"This is a tough field in which to develop new drugs, where current knowledge of the underlying biology of pathologies appears to be insufficient to generate reliable drug targets," Mitchell said.
Sanofi, GlaxoSmithKline, Merck, Novartis had cut back on research and development in the past two years, Mitchell noted. AstraZenecase earlier announced it was closing research labs in Canada and Sweden.
London-based AstraZeneca and Targacept Inc., based in Winston-Salem, North Carolina, signed a collaboration agreement to develop the drug in 2009.
J. Donald deBethizy, Targacept's president and chief executive officer, said the company had been reviewing its business to prepare for the possible failure of the drug, and had more than $225 million in cash to purse other avenues.
Hot Features
プレミアム
登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。
willlbone
10年前
Shaka_Zulu
11年前
Penny Roger$
12年前
JohnCM
12年前
shankapotamus
13年前
